# NCT05814354 (NCT05814354)

> SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05814354
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Conditions: Breast Cancer
- Interventions: SHR-A1811; Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
- Enrollment: 551
- Primary outcome: Progression-free Survival (PFS) Based on Blind Independent Video Review Committee (BIRC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 29
- YouTube: 1
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05814354

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05814354", "email": "<work email>"}; the inbox owner confirms by the emailed link.